Division of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Center for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Curr Neurol Neurosci Rep. 2023 Dec;23(12):857-867. doi: 10.1007/s11910-023-01321-y. Epub 2023 Nov 9.
Given the invasive and high-risk nature of brain surgery, the need for non-invasive biomarkers obtained from the peripheral blood is greatest in tumors of the central nervous system (CNS). In this comprehensive review, we highlight recent advances in blood biomarker development for adult and pediatric brain tumors.
We summarize recent blood biomarker development for CNS tumors across multiple key analytes, including peripheral blood mononuclear cells, cell-free DNA, cell-free RNA, proteomics, circulating tumor cells, and tumor-educated platelets. We also discuss methods for enhancing blood biomarker detection through transient opening of the blood-brain barrier. Although blood-based biomarkers are not yet used in routine neuro-oncology practice, this field is advancing rapidly and holds great promise for improved and non-invasive management of patients with brain tumors. Prospective and adequately powered studies are needed to confirm the clinical utility of any blood biomarker prior to widespread clinical implementation.
鉴于脑外科手术具有侵袭性和高风险的特点，中枢神经系统（CNS）肿瘤对来自外周血的非侵入性生物标志物的需求最大。在这篇全面的综述中，我们重点介绍了成人和儿童脑肿瘤血液生物标志物开发的最新进展。
我们总结了 CNS 肿瘤在多个关键分析物方面的最新血液生物标志物开发，包括外周血单核细胞、游离 DNA、游离 RNA、蛋白质组学、循环肿瘤细胞和肿瘤诱导的血小板。我们还讨论了通过短暂打开血脑屏障来增强血液生物标志物检测的方法。虽然基于血液的生物标志物尚未在神经肿瘤学常规实践中使用，但该领域正在迅速发展，为改善和非侵入性管理脑肿瘤患者带来了巨大的希望。在广泛临床应用之前，需要进行前瞻性和充分的研究来确认任何血液生物标志物的临床实用性。
